Drugs / Evuzamitide
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05635045 Comparator | Jul 2022 → May 2024 | — | Columbia University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Evuzamitide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05635045 ↗ |
| Modality | Peptide | “radiolabeled heparan sulfate proteoglycan-binding peptide 124I-evuzamitide” PMID 40439628 ↗ May 2025 |